BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26642837)

  • 1. Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
    Seedhouse SJ; Affronti HC; Karasik E; Gillard BM; Azabdaftari G; Smiraglia DJ; Foster BA
    Prostate; 2016 Mar; 76(4):359-68. PubMed ID: 26642837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma.
    Myers RB; Oelschlager D; Manne U; Coan PN; Weiss H; Grizzle WE
    Int J Cancer; 1999 Jul; 82(3):424-9. PubMed ID: 10399960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
    Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
    Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.
    Kim D; Gregory CW; French FS; Smith GJ; Mohler JL
    Am J Pathol; 2002 Jan; 160(1):219-26. PubMed ID: 11786415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.
    Røe K; Seierstad T; Kristian A; Mikalsen LT; Mælandsmo GM; van der Kogel AJ; Ree AH; Olsen DR
    Neoplasia; 2010 Oct; 12(10):818-25. PubMed ID: 20927320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
    Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
    J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors.
    Kochera M; Depinet TW; Pretlow TP; Giaconia JM; Edgehouse NL; Pretlow TG; Schwartz S
    Prostate; 1999 Sep; 41(1):7-11. PubMed ID: 10440870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
    Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
    Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
    Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
    Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
    Gregory CW; Kim D; Ye P; D'Ercole AJ; Pretlow TG; Mohler JL; French FS
    Endocrinology; 1999 May; 140(5):2372-81. PubMed ID: 10218991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft.
    Smitherman AB; Gregory CW; Mohler JL
    Prostate; 2003 Sep; 57(1):24-31. PubMed ID: 12886520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma.
    Myers RB; Oelschlager DK; Coan PN; Frost AR; Weiss HL; Manne U; Pretlow TG; Grizzle WE
    J Urol; 1999 Mar; 161(3):945-9. PubMed ID: 10022731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
    Chen CT; Gan Y; Au JL; Wientjes MG
    Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src controls castration recurrence of CWR22 prostate cancer xenografts.
    Su B; Gillard B; Gao L; Eng KH; Gelman IH
    Cancer Med; 2013 Dec; 2(6):784-92. PubMed ID: 24403252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence.
    Myers RB; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
    J Urol; 2001 Mar; 165(3):1027-32. PubMed ID: 11176534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.